Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

82.45
+2.843.57%
Post-market: 83.370.9200+1.12%17:23 EDT
Volume:1.56M
Turnover:128.90M
Market Cap:4.17B
PE:-19.61
High:84.75
Open:79.98
Low:79.10
Close:79.61
52wk High:88.02
52wk Low:13.37
Shares:50.54M
Float Shares:45.13M
Volume Ratio:1.26
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2037
EPS(LYR):-4.2037
ROE:-38.38%
ROA:-24.58%
PB:8.44
PE(LYR):-19.61

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems

Reuters
·
Mar 10

BUZZ-Dianthus jumps after nerve disease drug shows faster‑than‑expected response in trial

Reuters
·
Mar 10

Dianthus a ‘viable takeout target,’ says TD Cowen

TIPRANKS
·
Mar 10

Dianthus rises 26.3%

TIPRANKS
·
Mar 10

Dianthus price target raised to $130 from $47 at H.C. Wainwright

TIPRANKS
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Myomo (MYO) and Hims & Hers Health (HIMS)

TIPRANKS
·
Mar 09

Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Lantheus (LNTH)

TIPRANKS
·
Mar 09

Dianthus Shares Jump on Early Decision to OK CIDP Trial

Dow Jones
·
Mar 09

Dianthus price target raised to $110 from $63 at Truist

TIPRANKS
·
Mar 09

Dianthus Therapeutics FY 2025 net loss rises 91% to USD 162.34 million

Reuters
·
Mar 09

Dianthus Therapeutics Highlights Recent Business Achievements, Including Go Decision for Phase 3 Captivate Cidp Trial, and Reports Q4 and FY 2025 Financial Results

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Independent Dsmb Review Confirms Go Decision; No Related Serious Infections or Adverse Events

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Announces Early Go Decision Following Interim Responder Analysis in Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Maintains 300Mg/2Ml S.c. Q2w Dose; Plans to Remove 600Mg/4Ml S.c. Q2w Arm

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Expects to Provide Captivate Part B Top-Line Guidance by End of 2026

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics to Present Interim Phase 3 CAPTIVATE CIDP Trial Responder Results for Claseprubart

Reuters
·
Mar 09

Dianthus price target raised to $200 from $100 at Guggenheim

TIPRANKS
·
Mar 04

BRIEF-Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 04

Dianthus Therapeutics Grants 26,000 Inducement Stock Options to New Hires

Reuters
·
Mar 04

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

TIPRANKS
·
Mar 03